Results 111 to 120 of about 3,663 (172)

Barriers and Facilitators to the Use of Novel Injectable Lipid-Lowering Therapies in Patients with Dyslipidemia or Cardiovascular Disease: A Scoping Review. [PDF]

Medicina (Kaunas)
Caggianelli G, Iorfida M, Cavaliere R, Manzoli A, D'Angelo A, Scerbo F, Marti F, Mancin S, Cangelosi G, Rocco G, Vanzi V, Karuveettil V, Zega M, Donnoli C.   +13 more
europepmc   +1 more source

Antibody-Based Therapeutics for Hypercholesterolemia. [PDF]

Biologics
Tomlinson B, Chan P.
europepmc   +1 more source

Paradoxical LDL-C Increase after Switching from PCSK9 Inhibitors to Inclisiran: A Real-World Case Series. [PDF]

Acta Cardiol Sin
Chua SK, Hung HF, Jong BH, Chen LC.
europepmc   +1 more source

Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018-2019. [PDF]

Cureus
Okorigba EM, Jinadu KH, Muoghalu N, Adu E, Rose RS, Akinwumiju A.   +5 more
europepmc   +1 more source

Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke. [PDF]

CNS Drugs
Pu L, Liu J, Kong S, Joyama Y, Gong X, Ji X, Dong H.   +6 more
europepmc   +1 more source

TyG Index, BRI/TSH ratio, NPAR ratio, TAPSE/ PASP ratio…. [PDF]

Anatol J Cardiol
Erol Ç.
europepmc   +1 more source

Alirocumab for hypercholesterolaemia.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alirocumab for the treatment of hypercholesterolemia

Expert Opinion on Biological Therapy, 2017
Alirocumab is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered by subcutaneous injection every 2 weeks. Area covered: Herein, the authors discuss the background to inhibition of PCSK9 and the pharmacodynamics, pharmacokinetics and clinical trials with alirocumab.
Brian, Tomlinson, Miao, Hu, Yuzhen, Zhang, Paul, Chan, Zhong-Min, Liu   +4 more
openaire   +2 more sources

Alirocumab: A Review in Hypercholesterolemia

American Journal of Cardiovascular Drugs, 2016
Alirocumab (Praluent(®)) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered via subcutaneous injection every 2 weeks. Across ten phase III studies from the ODYSSEY clinical trial program in patients with heterozygous familial hypercholesterolemia (heFH) or nonfamilial hypercholesterolemia (nonFH),
Sarah L, Greig, Emma D, Deeks
openaire   +2 more sources